Immunitybio Inc (IBRX) earnings · rev $113.3M
These earnings events as JSON? API free 100/dayImmunitybio Inc (IBRX) is a biotechnology company listed on US.
This IBRX earnings page is the cached print — revenue, income, and the latest exhibit — not a live call transcript.
Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.
When the next IBRX 8-K Item 2.02 lands, this page should move. Until then the SEC archive is the source.
The change that matters: Revenue was up 668.3% from 2024-12-31 to 2025-12-31. An earnings headline that ignores that move is noise.
Not investment advice. Full IBRX research stays on the stock page; the tape stays on the quote page.
IBRX earnings FAQ
What are IBRX's latest revenue and net income?
Latest cached Immunitybio Inc (IBRX) revenue for Dec 31, 2025 was $113.3M. Net income was -$351.4M. Statements: https://lician.com/financials/ibrx
What is IBRX's latest diluted EPS?
Latest cached Immunitybio Inc (IBRX) diluted EPS for Dec 31, 2025 was -$0.38.
What period does the latest IBRX earnings print cover?
The latest cached Immunitybio Inc (IBRX) earnings print covers Dec 31, 2025. The prior cached period on this page is Dec 31, 2024.
How did IBRX revenue change from the prior cached period?
Cached Immunitybio Inc (IBRX) revenue was up 668.3% from $14.7M (Dec 31, 2024) to $113.3M (Dec 31, 2025). Statements: https://lician.com/financials/ibrx
Where are IBRX earnings listed?
Cached earnings facts for Immunitybio Inc (IBRX) are listed at https://lician.com/earnings/ibrx. Statements: https://lician.com/financials/ibrx
Not investment advice.